Along with insulin, therapies directed at improving gut barrier function, decreasing pancreatic and systemic inflammation, and treating hyperlipidemia have the potential to reduce complications and co‐morbid conditions in dogs with DM. This evidence concerns the gene INS and diabetes mellitus.